Shu Yamin相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer

一线恩考拉非尼联合西妥昔单抗和mFOLFOX6方案治疗BRAF V600E突变转移性结直肠癌的成本效益分析

期刊:iScience

影响因子:4.1

doi:10.1016/j.isci.2026.114977

Shu, Yamin; Shi, Fenghao; Xiong, Jinlin; Zheng, Jienan; Ding, Yiling; Zhang, Wenting; Xu, Pingping; Zhang, Qilin

发表日期：2026

文献求助收藏

Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China

在中国使用法瑞西单抗治疗糖尿病性黄斑水肿的成本效益分析

期刊:Journal of Comparative Effectiveness Research

影响因子:2.5

doi:10.57264/cer-2025-0190

Shi, Fenghao; Tan, Shuhua; Shu, Yamin; Liu, Tianyi; Xia, Yan; Buehrer, Christian; Han, Sheng

发表日期：2026

文献求助收藏

Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China.

在中国，沙妥珠单抗替鲁莫替康与化疗治疗转移性三阴性乳腺癌患者的成本效益分析

影响因子:7.9

doi:10.1016/j.breast.2025.104550

Shu Yamin, Tang Ying, Ding Yiling, Xu Pingping, Zhang Qilin

发表日期：2025

文献求助收藏

Myelopreservation effect of trilaciclib in extensive-stage small cell lung cancer (ES-SCLC): a systematic review and meta-analysis with trial sequential analysis of randomized clinical trials

曲拉西利在广泛期小细胞肺癌（ES-SCLC）中的骨髓保护作用：一项系统评价和荟萃分析，以及随机临床试验的序贯分析

期刊:Translational Lung Cancer Research

影响因子:3.5

doi:10.21037/tlcr-2025-67

Ding, Yiling; Deng, Zhijie; Yuan, Xun; Shu, Yamin; Chen, Jing; Cao, Shiyi; Chu, Qian

细胞生物学

发表日期：2025

文献求助收藏

Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial

在中国，一项关于卡多尼利单抗联合铂类化疗（加或不加贝伐单抗）一线治疗持续性、复发性或转移性宫颈癌的成本效益分析：COMPASSION-16试验

期刊:Journal of Pharmaceutical Policy and Practice

影响因子:2.5

doi:10.1080/20523211.2025.2464781

Ding, Yiling; Wang, Chunping; Shu, Yamin; Wang, Jinglin; Zhang, Qilin

发表日期：2025

文献求助收藏

Post-marketing safety surveillance for the recombinant zoster vaccine (Shingrix), vaccine adverse event reporting system, United States, October 2017-April 2024

重组带状疱疹疫苗（欣格瑞）上市后安全性监测，疫苗不良事件报告系统，美国，2017年10月至2024年4月

期刊:Preventive Medicine Reports

影响因子:2.4

doi:10.1016/j.pmedr.2025.102981

Shu, Yamin; Cheng, Wenxin; He, Xucheng; Huang, Liu; Chen, Wei; Zhang, Qilin

发表日期：2025

文献求助收藏

Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study

在美国和中国，阿特珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗方案的成本效益分析：一项模型比较研究

期刊:BMJ Open

影响因子:2.3

doi:10.1136/bmjopen-2024-094804

Liu, Lulu; Wang, Lei; Ding, Yiling; Zhang, Qilin; Shu, Yamin

细胞生物学

发表日期：2025

文献求助收藏

Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China

中国50岁及以上成年人使用重组带状疱疹疫苗和减毒活疫苗的成本效益分析

期刊:Pharmacoeconomics-Open

影响因子:2.1

doi:10.1007/s41669-025-00604-z

Liu, Lulu; Zhang, Qilin; Shu, Yamin; Wang, Lei; Shuai, Zhenqingyun; Chu, Mingming; Zhang, Zhe; Zhang, Rong

发表日期：2025

文献求助收藏

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

阿达木单抗在儿童中的不良事件特征：一项不成比例性分析

期刊:Pharmaceuticals

影响因子:4.8

doi:10.3390/ph17081028

Zhang, Wenting; Xu, Ziqi; Shu, Yamin; Shu, Sainan; Zhang, Qilin

发表日期：2024

文献求助收藏

Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system

索托拉西布上市后安全性问题：基于FDA不良事件报告系统的比例失衡分析

影响因子:3.6

doi:10.1016/j.heliyon.2024.e30437

Ding, Yiling; Su, Hongyan; Shu, Yamin; Chen, Jing

发表日期：2024

文献求助收藏